TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion.

Saved in:
Bibliographic Details
Title: TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion.
Authors: Debesset A; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France., Pilon C; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France.; CIC Biotherapy, Fédération hospitalo-Universitaire TRUE, AP-HP, GH Henri Mondor, Créteil, France., Meunier S; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France., Cuelenaere-Bonizec O; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France., Richer W; INSERM U932, Institute Curie Research Center, PSL Research University, Paris, France.; Department of Translational Research, Institut Curie Research center, PSL Research University, Paris, France., Thiolat A; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France., Houppe C; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France., Ponzo M; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France., Magnan J; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France., Caron J; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France., Caudana P; INSERM U932, Institute Curie Research Center, PSL Research University, Paris, France.; Department of Translational Research, Institut Curie Research center, PSL Research University, Paris, France., Tosello Boari J; INSERM U932, Institute Curie Research Center, PSL Research University, Paris, France.; Department of Translational Research, Institut Curie Research center, PSL Research University, Paris, France., Baulande S; Institut Curie Research Center, ICGex Next-Generation Sequencing Platform, Single Cell Initiative, PSL Research University, Paris, France., To NH; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France.; Department of Radiation Oncology, Henri Mondor Breast Center, AP-HP, GH Henri Mondor, Paris, France., Salomon BL; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France., Piaggio E; INSERM U932, Institute Curie Research Center, PSL Research University, Paris, France.; Department of Translational Research, Institut Curie Research center, PSL Research University, Paris, France., Cascone I; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France jose.cohen@inserm.fr ilaria.cascone@inserm.fr., Cohen JL; INSERM, IMRB U955, Université Paris-Est Créteil Val de Marne, Créteil, France jose.cohen@inserm.fr ilaria.cascone@inserm.fr.; CIC Biotherapy, Fédération hospitalo-Universitaire TRUE, AP-HP, GH Henri Mondor, Créteil, France.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Nov 19; Vol. 12 (11). Date of Electronic Publication: 2024 Nov 19.
Publication Type: Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2024-008898